Hepatocellular carcinoma: current questions and future directions.
作者信息
Gish Robert G
机构信息
Stanford Hospital and Medical Center, Stanford, California.
出版信息
Clin Adv Hematol Oncol. 2015 Mar;13(3):176-9.
PMID:26352425
Abstract
摘要
相似文献
1
Hepatocellular carcinoma: current questions and future directions.
Clin Adv Hematol Oncol. 2015 Mar;13(3):176-9.
2
The role of sorafenib in hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2015 Apr;13(4):232-4.
3
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
4
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.
5
Treatment of intermediate-stage hepatocellular carcinoma.
Clin Adv Hematol Oncol. 2015 Aug;13(8):501-3.
6
Next Generation of Preclinical Liver Cancer Models.
Clin Cancer Res. 2015 Oct 1;21(19):4254-6. doi: 10.1158/1078-0432.CCR-15-1152. Epub 2015 Jul 13.
7
Managing localized unresectable hepatocellular carcinoma.
JAAPA. 2015 Jan;28(1):27-34. doi: 10.1097/01.JAA.0000458854.46279.d8.
8
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Future Oncol. 2015;11(16):2263-6. doi: 10.2217/fon.15.161.
9
10
Hepatocellular carcinoma: options for diagnosing and managing a deadly disease.
Cleve Clin J Med. 2013 Oct;80(10):645-53. doi: 10.3949/ccjm.80a.12163.
Zotero 插件